Plasma transferrin and hemopexin are associated with altered A beta uptake and cognitive decline in Alzheimer's disease pathology
Azhaar Ashraf, Nicholas J Ashton, Pratishtha Chatterjee, Kathryn Goozee, Kai-Kai Shen, Jurgen Fripp, David Ames, Christopher Rowe, Colin L Masters, Victor Villemagne, Abdul Hye, Ralph Nigel Martins, Po-Wah So
ALZHEIMERS RESEARCH & THERAPY | BMC | Published : 2020
BACKGROUND: Heme and iron homeostasis is perturbed in Alzheimer's disease (AD); therefore, the aim of the study was to examine the levels and association of heme with iron-binding plasma proteins in cognitively normal (CN), mild cognitive impairment (MCI), and AD individuals from the Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) and Kerr Anglican Retirement Village Initiative in Ageing Health (KARVIAH) cohorts. METHODS: Non-targeted proteomic analysis by high-resolution mass spectrometry was performed to quantify relative protein abundances in plasma samples from 144 CN individuals from the AIBL and 94 CN from KARVIAH cohorts and 21 MCI and 25 AD from AIBL cohor..View full abstract
AA is supported by the Biotechnology and Biological Sciences Research Council (BBRSC). N.J.A. was supported by Rosetree Trust for this study. P.C. is supported by KaRa Institute of Neurological Diseases (KaRa MINDS) and Macquarie University. K.G. is funded by Anglicare (Sydney, Australia). R.M. is funded jointly by Edith Cowan University and Macquarie University. A.H. is funded by the Research Centre for Mental Health and Biomedical Research Unit for dementia. PWS is funded by King's College London. All other authors acknowledge that they received no funding in support of this research.